AveXis, Inc. (NASDAQ:AVXS) VP Sukumar Nagendran sold 1,780 shares of the firm’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $94.77, for a total value of $168,690.60. Following the sale, the vice president now directly owns 1,780 shares in the company, valued at approximately $168,690.60. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Sukumar Nagendran also recently made the following trade(s):
- On Wednesday, November 1st, Sukumar Nagendran sold 1,780 shares of AveXis stock. The stock was sold at an average price of $101.26, for a total value of $180,242.80.
- On Monday, October 2nd, Sukumar Nagendran sold 1,780 shares of AveXis stock. The stock was sold at an average price of $97.25, for a total value of $173,105.00.
AveXis, Inc. (AVXS) traded down $0.34 during trading hours on Wednesday, reaching $93.50. The company had a trading volume of 350,500 shares, compared to its average volume of 426,264. AveXis, Inc. has a 12-month low of $44.68 and a 12-month high of $108.27.
Large investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. grew its stake in AveXis by 41.7% during the 2nd quarter. Russell Investments Group Ltd. now owns 24,871 shares of the company’s stock worth $2,043,000 after buying an additional 7,321 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of AveXis by 31.8% in the 2nd quarter. Vanguard Group Inc. now owns 1,575,205 shares of the company’s stock valued at $129,419,000 after purchasing an additional 380,396 shares during the last quarter. Tocqueville Asset Management L.P. purchased a new position in shares of AveXis in the 2nd quarter valued at approximately $552,000. TimesSquare Capital Management LLC purchased a new position in shares of AveXis in the 2nd quarter valued at approximately $6,162,000. Finally, BB Biotech AG grew its stake in shares of AveXis by 21.0% in the 2nd quarter. BB Biotech AG now owns 402,800 shares of the company’s stock valued at $33,094,000 after purchasing an additional 70,000 shares during the last quarter. Hedge funds and other institutional investors own 92.88% of the company’s stock.
Several equities research analysts have recently weighed in on the company. Royal Bank Of Canada reissued a “hold” rating and set a $92.00 target price on shares of AveXis in a research report on Thursday, November 2nd. Canaccord Genuity assumed coverage on AveXis in a research report on Thursday, October 26th. They set a “hold” rating and a $110.00 target price on the stock. Zacks Investment Research lowered AveXis from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. Citigroup raised their target price on AveXis from $100.00 to $116.00 and gave the stock a “buy” rating in a research report on Monday, October 2nd. Finally, UBS reissued a “buy” rating and set a $122.00 target price (up previously from $95.00) on shares of AveXis in a research report on Tuesday, October 3rd. Three investment analysts have rated the stock with a sell rating, three have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. AveXis currently has an average rating of “Buy” and a consensus price target of $110.67.
TRADEMARK VIOLATION NOTICE: “AveXis, Inc. (AVXS) VP Sukumar Nagendran Sells 1,780 Shares of Stock” was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.com-unik.info/2017/12/06/avexis-inc-avxs-vp-sukumar-nagendran-sells-1780-shares-of-stock.html.
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
What are top analysts saying about AveXis Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AveXis Inc. and related companies.